These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15076244)

  • 1. Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data.
    Flandre P; Alcais A; Descamps D; Morand-Joubert L; Joly V
    J Acquir Immune Defic Syndr; 2004 Mar; 35(3):286-92. PubMed ID: 15076244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases.
    Flandre P; Durier C; Descamps D; Launay O; Joly V
    J Acquir Immune Defic Syndr; 2002 May; 30(1):59-64. PubMed ID: 12048363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases.
    Marschner IC; Betensky RA; DeGruttola V; Hammer SM; Kuritzkes DR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):220-7. PubMed ID: 10077169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.
    Flandre P; Marcelin AG; Calvez V;
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):448-454. PubMed ID: 28653971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials.
    Hughes MD
    Stat Med; 2000 Dec; 19(23):3171-91. PubMed ID: 11113952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling HIV-RNA viral load in vertically infected children.
    Gray L; Cortina-Borja M; Newell ML
    Stat Med; 2004 Mar; 23(5):769-81. PubMed ID: 14981674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weighted Kaplan-Meier estimators motivating to estimate HIV-1 RNA reduction censored by a limit of detection.
    Ahmed I; Flandre P
    Stat Med; 2020 Mar; 39(7):968-983. PubMed ID: 31981243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit.
    Chen YH; Gould AL; Nessly ML
    Stat Med; 2005 Jan; 24(2):211-28. PubMed ID: 15558832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative investigation of methods for longitudinal data with limits of detection through a case study.
    Fu P; Hughes J; Zeng G; Hanook S; Orem J; Mwanda OW; Remick SC
    Stat Methods Med Res; 2016 Feb; 25(1):153-66. PubMed ID: 22504231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1123-33. PubMed ID: 10954887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors.
    Soret P; Avalos M; Wittkop L; Commenges D; Thiébaut R
    BMC Med Res Methodol; 2018 Dec; 18(1):159. PubMed ID: 30514234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods.
    Journot V; Chêne G; Joly P; Savès M; Jacqmin-Gadda H; Molina JM; Salamon R;
    Control Clin Trials; 2001 Dec; 22(6):639-58. PubMed ID: 11738121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials.
    Flandre P; Pinçon C; Aboulker JP; Brun-Vézinet F; Pialoux G; Raffi F; Descamps D
    HIV Clin Trials; 2006; 7(3):116-24. PubMed ID: 16880168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy.
    Percus JK; Percus OE; Markowitz M; Ho DD; Di Mascio M; Perelson AS
    Bull Math Biol; 2003 Mar; 65(2):263-77. PubMed ID: 12675332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity studies for quantitative assays: use of censored data analysis.
    Weusten JJ; Wouters PA; van Zuijlen MC
    Stat Med; 2003 Dec; 22(23):3629-40. PubMed ID: 14652865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antiviral treatment on the shedding of HIV-1 in semen.
    Vernazza PL; Gilliam BL; Flepp M; Dyer JR; Frank AC; Fiscus SA; Cohen MS; Eron JJ
    AIDS; 1997 Aug; 11(10):1249-54. PubMed ID: 9256943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixture models for quantitative HIV RNA data.
    Moulton LH; Curriero FC; Barroso PF
    Stat Methods Med Res; 2002 Aug; 11(4):317-25. PubMed ID: 12197299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
    Rae S; Raboud JM; Conway B; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg MA; Robinson P; Myers M; Hall D; Montaner JS
    AIDS; 1998 Nov; 12(16):2185-92. PubMed ID: 9833860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of dynamical model parameters taking into account undetectable marker values.
    Thiébaut R; Guedj J; Jacqmin-Gadda H; Chêne G; Trimoulet P; Neau D; Commenges D
    BMC Med Res Methodol; 2006 Aug; 6():38. PubMed ID: 16879756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment.
    Bartlett JA; DeMasi R; Dawson D; Hill A
    J Infect Dis; 1998 Dec; 178(6):1803-5. PubMed ID: 9815239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.